Genelux Reports Encouraging Interim Lung Cancer Trial Data for Olvi-Vec, Showing Promising Efficacy and Tolerability

summarizeSummary

Genelux Corporation announced positive interim results from two ongoing clinical trials evaluating systemic administration of Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), demonstrating encouraging efficacy and a favorable safety profile.

check_boxKey Events

• Positive SCLC Trial Results

  The Phase 1b/2 SCLC trial reported an Overall Response Rate (ORR) of 33% (3/9 patients) and a Disease Control Rate (DCR) of 67% (6/9 patients) in platinum-relapsed/refractory patients. The highest dose cohort showed an ORR of 67% (2/3 patients), suggesting a dose-response trend, with tumor shrinkage up to 85%.

• Encouraging NSCLC Trial Data

  The Phase 2 VIRO-25 trial in advanced or metastatic recurrent NSCLC patients demonstrated a DCR of 60% (3/5 patients), with tumor size changes ranging from -18.9% to -22.7% in responding patients.

• Favorable Safety Profile

  Olvi-Vec was generally well tolerated in both the SCLC and NSCLC trials, indicating a positive safety profile for systemic administration.

• Upcoming Milestones

  Additional interim data readouts for both lung cancer trials are expected throughout 2026, alongside topline data from the Phase 3 ovarian cancer trial in the second half of 2026.

auto_awesomeAnalysis

Genelux Corporation announced positive interim results from two clinical trials for its lead investigational asset, Olvi-Vec, in difficult-to-treat lung cancers. The Phase 1b/2 SCLC trial showed an overall response rate (ORR) of 33% and a disease control rate (DCR) of 67% in platinum-relapsed/refractory small cell lung cancer patients, with a notable 67% ORR in the highest dose cohort suggesting a dose-response trend. Exploratory durability signals were also observed. The Phase 2 VIRO-25 trial in non-small cell lung cancer patients reported a DCR of 60%. In both trials, Olvi-Vec was generally well tolerated. These results are significant as they support the systemic delivery of Olvi-Vec and indicate potential for future registrational trials, de-risking the asset and expanding its potential market.